V​inod Khosla is an entrepreneur, investor, and technology fan. He is the founder of Khosla Ventures, focused on impactful technology investments in software, AI, robotics, 3D printing, healthcare and more​.  Mr. Khosla was a co-founder of Daisy systems and founding CEO of Sun Microsystems where he pioneered open systems and commercial RISC processors. One of Mr. Khosla’s greatest passions is being a mentor to entrepreneurs, assisting entrepreneurs and helping them build technology-based businesses. ​Mr. Khosla is driven by the desire to make positive impact through using to technology to reinvent societal infrastructure and multiply resources.  He is also passionate about Social Entrepreneurship. Vinod holds a Bachelor of Technology in Electrical Engineering from IIT, New Delhi, a Master's in Biomedical Engineering from Carnegie Mellon University and an MBA from the Stanford Graduate School of Business. 

Brian Kobilka, MD is Professor of Molecular and Cellular Physiology, and Hélène Irwin Fagan Chair in Cardiology at Stanford University School of Medicine. He received a Bachelor of Science Degrees in Biology and Chemistry from the University of Minnesota, Duluth in 1977. He graduated from Yale University School of Medicine in 1981, and completed residency training in Internal Medicine at Washington University School of Medicine in St. Louis in 1984. From 1984-1989 he was a postdoctoral fellow in the laboratory of Robert Lefkowitz at Duke University. In 1990 he joined the faculty of Medicine and Molecular and Cellular Physiology at Stanford University. Research in the Kobilka lab focuses on the structure and mechanism of action of G protein coupled receptors (GPCRs), which constitute the largest family of receptors for hormones and neurotransmitters in the human genome. GPCRs are the largest group of targets for new therapeutics for a very broad spectrum of diseases. In 2012, Kobilka was awarded the Nobel Prize in Chemistry for his work on GPCRs. He is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences.  

Rachel Sha is the Vice President of Digital Business Development & Licensing at Sanofi. She leads a team of Business Development professionals driving transactions from identifying new opportunities to closing deals across therapeutic areas in digital health with the goal of discovering, developing and bringing to market solutions that improve outcomes and experience at reduced costs. Some partnering deals Rachel has led include Science 37, which enables decentralized clinical studies, and Evidation Health, a leader in behavior analytics. She co-led the transaction with Verily Life Sciences in diabetes and was the alliance manager for the collaboration with Verily Life Sciences , leading the joint venture formation, called Onduo. Additionally, Rachel serves on the Life Sciences Council of Springboard Enterprises, which is focused on supporting women-led companies grow and expand, is a judge for Mass Challenge and MIT Lemelson Student Prize. She joined Genzyme in 2005 and has held roles with increasing responsibility in Business Development, Corporate Development and Global Marketing & Strategy for Genzyme and Sanofi. Prior to Sanofi, Rachel was a manager at Accenture, where she focused on a broad range of business issues from strategy to process to technology implementation across a diverse set of industries with focus in electronics & high tech in particular. Rachel holds a Bachelor of Science degree in Chemistry from Massachusetts Institute of Technology and an MBA from Harvard Business School.

Maya is the founder and CEO of Outcomes4Me, a private company focusing on providing patients with personalized treatment options and outcomes information. She also serves on the Board of Directors of Transgene, a publicly traded biotech company focused on discovering and developing immune-targeted therapies for the treatment of cancer and infectious diseases. Prior to Outcomes4Me, Maya was Senior Vice President and Global Head of Oncology Policy and Market Access at Novartis as well as Head of Global R&D Strategy, Science Policy & External Innovation at Sanofi. Before joining the pharma industry, she spent over seven years at the Boston Consulting Group (BCG) and was a founding member of BCG’s Strategy Institute. Maya holds dual undergraduate degrees in Biology and Electrical Engineering & Computer Science (EECS), a Master of Science in Toxicology, a Master of Engineering in EECS, and a Doctor of Science in Electrical Engineering, Computer Science and Systems Biology, all from the Massachusetts Institute of Technology.

Mark DePristo leads the Genomics team in Google Brain that applies deep learning in TensorFlow to genomics problems to create tools such as DeepVariant. Before joining Google he was Vice President of Informatics at SynapDx, a Google Ventures-backed startup developing a blood-based test for Autism. As Co-Director of Medical and Population Genetics at the Broad Institute from 2008-2013 Mark created and led the team that developed the GATK, the dominant software for processing next-generation DNA sequencing data. He has an BA in Computer Science and Math from Northwestern University, a PhD in Biochemistry from the University of Cambridge as a Marshall Scholar, did a postdoc at Harvard University in evolutionary biology. Dr. DePristo's academic articles are widely published and have received more than 48,000 citations.